Interaction between NSCLC Cells, CD8⁺ T-Cells and Immune Checkpoint Inhibitors Potentiates Coagulation and Promotes Metabolic Remodeling-New Cues on CAT-VTE.

ABSTRACT:

Background

Cancer-associated thrombosis (CAT) and venous thromboembolism (VTE) are frequent cancer-related complications associated with high mortality; thus, this urges the identification of predictive markers. Immune checkpoint inhibitors (ICIs) used in cancer immunotherapy allow T-cell activation against cancer cells. Retrospective studies showed increased VTE following ICI administration in some patients. Non-small cell lung cancer (NSCLC) patients are at high risk of thrombosis and thus, the adoption of immunotherapy, as a first-line treatment, seems to be associated with coagulation-fibrinolysis derangement.

Methods

We pharmacologically modulated NSCLC cell lines in co-culture with CD8⁺ T-cells (TCD8⁺) and myeloid-derived suppressor cells (MDSCs),

SUBMITTER: Freitas-Dias C 

PROVIDER: S-EPMC10886748 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature